Open AccessThe basophil activation test reflects the severity and the threshold of allergic reactions to peanut – a double‐blind‐placebo‐controlled peanut challenge study
Author(s) -
Santos Alexandra,
Douiri Abdel,
Stephens Alick,
Radulovic Suzana,
Toit George,
Turcanu Victor,
Lack Gideon
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s3-p25
Subject(s) - basophil activation , medicine , peanut allergy , anaphylaxis , basophil , allergy , placebo , allergen , immunology , immunoglobulin e , cd63 , gastroenterology , food allergy , antibody , pathology , microrna , biochemistry , chemistry , alternative medicine , microvesicles , gene
Results 44 peanut allergic children (median age 5 years) reacted to peanut on DBPCPC with clinical symptoms than ranged from oral allergy syndrome to anaphylaxis. 61% of patients reacted to 0.1g of peanut protein. The mean %CD63+ basophil at 10 and 100 ng/ml of PE was independently associated with severity (p=0.012) whilst CD-sens (1/EC50x100) was independently associated with threshold (p=0.039) of allergic reactions to peanut. Severity and threshold parameters were correlated both at the clinical (Rs=-0.38; p=0.013) and at the basophil level (Rs=0.65; p<0.001).